Migrating to Long-Read Sequencing for Clinical Routine BCR-ABL1 TKI Resistance Mutation Screening.

IF 2.5 Q2 MATHEMATICAL & COMPUTATIONAL BIOLOGY
Cancer Informatics Pub Date : 2022-07-15 eCollection Date: 2022-01-01 DOI:10.1177/11769351221110872
Wesley Schaal, Adam Ameur, Ulla Olsson-Strömberg, Monica Hermanson, Lucia Cavelier, Ola Spjuth
{"title":"Migrating to Long-Read Sequencing for Clinical Routine <i>BCR-ABL1</i> TKI Resistance Mutation Screening.","authors":"Wesley Schaal,&nbsp;Adam Ameur,&nbsp;Ulla Olsson-Strömberg,&nbsp;Monica Hermanson,&nbsp;Lucia Cavelier,&nbsp;Ola Spjuth","doi":"10.1177/11769351221110872","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>The aim of this project was to implement long-read sequencing for BCR-ABL1 TKI resistance mutation screening in a clinical setting for patients undergoing treatment for chronic myeloid leukemia.</p><p><strong>Materials and methods: </strong>Processes were established for registering and transferring samples from the clinic to an academic sequencing facility for long-read sequencing. An automated analysis pipeline for detecting mutations was established, and an information system was implemented comprising features for data management, analysis and visualization. Clinical validation was performed by identifying BCR-ABL1 TKI resistance mutations by Sanger and long-read sequencing in parallel. The developed software is available as open source via GitHub at https://github.com/pharmbio/clamp.</p><p><strong>Results: </strong>The information system enabled traceable transfer of samples from the clinic to the sequencing facility, robust and automated analysis of the long-read sequence data, and communication of results from sequence analysis in a reporting format that could be easily interpreted and acted upon by clinical experts. In a validation study, all 17 resistance mutations found by Sanger sequencing were also detected by long-read sequencing. An additional 16 mutations were found only by long-read sequencing, all of them with frequencies below the limit of detection for Sanger sequencing. The clonal distributions of co-existing mutations were automatically resolved through the long-read data analysis. After the implementation and validation, the clinical laboratory switched their routine protocol from using Sanger to long-read sequencing for this application.</p><p><strong>Conclusions: </strong>Long-read sequencing delivers results with higher sensitivity compared to Sanger sequencing and enables earlier detection of emerging TKI resistance mutations. The developed processes, analysis workflow, and software components lower barriers for adoption and could be extended to other applications.</p>","PeriodicalId":35418,"journal":{"name":"Cancer Informatics","volume":" ","pages":"11769351221110872"},"PeriodicalIF":2.5000,"publicationDate":"2022-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9290162/pdf/","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Informatics","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/11769351221110872","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"MATHEMATICAL & COMPUTATIONAL BIOLOGY","Score":null,"Total":0}
引用次数: 1

Abstract

Objective: The aim of this project was to implement long-read sequencing for BCR-ABL1 TKI resistance mutation screening in a clinical setting for patients undergoing treatment for chronic myeloid leukemia.

Materials and methods: Processes were established for registering and transferring samples from the clinic to an academic sequencing facility for long-read sequencing. An automated analysis pipeline for detecting mutations was established, and an information system was implemented comprising features for data management, analysis and visualization. Clinical validation was performed by identifying BCR-ABL1 TKI resistance mutations by Sanger and long-read sequencing in parallel. The developed software is available as open source via GitHub at https://github.com/pharmbio/clamp.

Results: The information system enabled traceable transfer of samples from the clinic to the sequencing facility, robust and automated analysis of the long-read sequence data, and communication of results from sequence analysis in a reporting format that could be easily interpreted and acted upon by clinical experts. In a validation study, all 17 resistance mutations found by Sanger sequencing were also detected by long-read sequencing. An additional 16 mutations were found only by long-read sequencing, all of them with frequencies below the limit of detection for Sanger sequencing. The clonal distributions of co-existing mutations were automatically resolved through the long-read data analysis. After the implementation and validation, the clinical laboratory switched their routine protocol from using Sanger to long-read sequencing for this application.

Conclusions: Long-read sequencing delivers results with higher sensitivity compared to Sanger sequencing and enables earlier detection of emerging TKI resistance mutations. The developed processes, analysis workflow, and software components lower barriers for adoption and could be extended to other applications.

Abstract Image

Abstract Image

Abstract Image

迁移到长读测序用于临床常规BCR-ABL1 TKI抗性突变筛选。
目的:该项目的目的是在接受慢性髓性白血病治疗的患者的临床环境中实施BCR-ABL1 TKI耐药突变筛查的长读测序。材料和方法:建立了从临床登记和转移样品到学术测序设施进行长读测序的流程。建立了突变检测自动化分析管道,实现了具有数据管理、分析和可视化功能的信息系统。通过Sanger和长读测序平行鉴定BCR-ABL1 TKI耐药突变进行临床验证。开发的软件可通过GitHub (https://github.com/pharmbio/clamp.Results:)以开源形式获得。该信息系统可将样品从诊所转移到测序设施,对长读序列数据进行可靠的自动化分析,并以报告格式交流序列分析结果,该报告格式易于临床专家解释和采取行动。在一项验证性研究中,Sanger测序发现的所有17个耐药突变也可以通过长读测序检测到。另外16个突变仅通过长读测序被发现,它们的频率都低于桑格测序的检测极限。通过长读数据分析,自动解析共存突变的克隆分布。在实施和验证后,临床实验室将其常规方案从使用桑格测序改为长读测序。结论:与Sanger测序相比,长读测序的结果具有更高的灵敏度,并且能够更早地检测到新出现的TKI抗性突变。开发的过程、分析工作流和软件组件降低了采用的门槛,并且可以扩展到其他应用程序。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Cancer Informatics
Cancer Informatics Medicine-Oncology
CiteScore
3.00
自引率
5.00%
发文量
30
审稿时长
8 weeks
期刊介绍: The field of cancer research relies on advances in many other disciplines, including omics technology, mass spectrometry, radio imaging, computer science, and biostatistics. Cancer Informatics provides open access to peer-reviewed high-quality manuscripts reporting bioinformatics analysis of molecular genetics and/or clinical data pertaining to cancer, emphasizing the use of machine learning, artificial intelligence, statistical algorithms, advanced imaging techniques, data visualization, and high-throughput technologies. As the leading journal dedicated exclusively to the report of the use of computational methods in cancer research and practice, Cancer Informatics leverages methodological improvements in systems biology, genomics, proteomics, metabolomics, and molecular biochemistry into the fields of cancer detection, treatment, classification, risk-prediction, prevention, outcome, and modeling.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信